

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
19 June 2025 (19.06.2025)



(10) International Publication Number
WO 2025/128723 A1

(51) International Patent Classification:

A61K 31/439 (2006.01) A61P 25/34 (2006.01)
A24B 15/16 (2020.01) C07D 471/18 (2006.01)
A61K 9/20 (2006.01) A61K 31/465 (2006.01)
A61K 9/48 (2006.01)

(21) International Application Number:

PCT/US2024/059604

(22) International Filing Date:

11 December 2024 (11.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/608,959 12 December 2023 (12.12.2023) US

(71) Applicant: ACHIEVE LIFE SCIENCES, INC. [US/US];

22722 29th Dr. SE, Suite 100, Bothell, Washington 98021 (US).

(72) Inventors: DELGADO RUEDA, Marco Antonio; 61

Cophall Lane, Chalfont St Peter, Bucks Buckinghamshire SL90DS (GB). MILLER, Kelly; c/o Achieve Life Sciences, Inc. 22722 29th Dr. SE, Suite 100, Bothell, Washington 98021 (US). DONNELLY, Craig; c/o Achieve Life

Sciences, Inc., 22722 29th Dr. SE, Suite 100, Bothell, Washington 98021 (US). ELDER, David; Cerebro CMC Limited, Stevenage Bioscience, Catalyst, Incubator Building, Gummels Wood Road, Stevenage Hertfordshire SG1 2FX (GB). SEARLE, Andrew; Cerebro CMC Limited, Stevenage Bioscience, Catalyst, Incubator Building, Gummels Wood Road, Stevenage Hertfordshire SG1 2FX (GB).

(74) Agent: FOURNIER, David et al.; P.O. Box 1247, Seattle, Washington 98111-1247 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, CV,

(54) Title: CYTISINE FORMULATIONS




FIG. 7A

(57) Abstract: Provided herein is a cytosine formulation comprising cytosine, a nitrite scavenger, a glidant, a lubricant, a buffering agent and one or more fillers, wherein, upon storage of the composition at about 60 °C, the amount of N-nitrosocytosine relative to a total weight of cytosine is 4.2 ng/mg or less after about 30 days.

[Continued on next page]

GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*